Category Archives: Biotechnology

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So, the natural question for G&E Herbal Biotechnology (GTSM:4911) shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

Check out our latest analysis for G&E Herbal Biotechnology

A company's cash runway is calculated by dividing its cash hoard by its cash burn. When G&E Herbal Biotechnology last reported its balance sheet in September 2020, it had zero debt and cash worth NT$121m. In the last year, its cash burn was NT$9.2m. So it had a very long cash runway of many years from September 2020. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. The image below shows how its cash balance has been changing over the last few years.

In our view, G&E Herbal Biotechnology doesn't yet produce significant amounts of operating revenue, since it reported just NT$24m in the last twelve months. Therefore, for the purposes of this analysis we'll focus on how the cash burn is tracking. The 71% reduction in its cash burn over the last twelve months may be good for protecting the balance sheet but it hardly points to imminent growth. Admittedly, we're a bit cautious of G&E Herbal Biotechnology due to its lack of significant operating revenues. We prefer most of the stocks on this list of stocks that analysts expect to grow.

There's no doubt G&E Herbal Biotechnology's rapidly reducing cash burn brings comfort, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund further growth. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

G&E Herbal Biotechnology's cash burn of NT$9.2m is about 0.5% of its NT$1.8b market capitalisation. That means it could easily issue a few shares to fund more growth, and might well be in a position to borrow cheaply.

As you can probably tell by now, we're not too worried about G&E Herbal Biotechnology's cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. And even its cash burn reduction was very encouraging. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Taking a deeper dive, we've spotted 3 warning signs for G&E Herbal Biotechnology you should be aware of, and 2 of them are a bit unpleasant.

Of course G&E Herbal Biotechnology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

PromotedWhen trading G&E Herbal Biotechnology or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

More here:
G&E Herbal Biotechnology (GTSM:4911) Is In A Strong Position To Grow Its Business - Simply Wall St

Matinas BioPharma Holdings Inc (MTNB) is around the top of the Biotechnology industry according to InvestorsObserver. MTNB received an overall rating of 79, which means that it scores higher than 79 percent of all stocks. Matinas BioPharma Holdings Inc also achieved a score of 95 in the Biotechnology industry, putting it above 95 percent of Biotechnology stocks. Biotechnology is ranked 26 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Matinas BioPharma Holdings Inc (MTNB) stock has fallen -6.69% while the S&P 500 has risen 0.33% as of 3:17 PM on Friday, Jan 8. MTNB has fallen -$0.11 from the previous closing price of $1.57 on volume of 5,656,629 shares. Over the past year the S&P 500 is up 16.55% while MTNB has fallen -23.04%. MTNB lost -$0.12 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Matinas BioPharma Holdings Inc (MTNB) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the article here:
Is Matinas BioPharma Holdings Inc (MTNB) The Right Choice in Biotechnology? - InvestorsObserver

BioXcel Therapeutics Inc (BTAI) is around the top of the Biotechnology industry according to InvestorsObserver. BTAI received an overall rating of 85, which means that it scores higher than 85 percent of all stocks. BioXcel Therapeutics Inc also achieved a score of 98 in the Biotechnology industry, putting it above 98 percent of Biotechnology stocks. Biotechnology is ranked 26 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

BioXcel Therapeutics Inc (BTAI) stock is lower by -3.89% while the S&P 500 is up 0.33% as of 3:19 PM on Friday, Jan 8. BTAI is down -$2.14 from the previous closing price of $54.95 on volume of 485,305 shares. Over the past year the S&P 500 is higher by 16.55% while BTAI is up 330.75%. BTAI lost -$3.37 per share the over the last 12 months.

Click Here to get the full Stock Score Report on BioXcel Therapeutics Inc (BTAI) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Go here to read the rest:
Is BioXcel Therapeutics Inc (BTAI) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

A rating of 79 puts Intellia Therapeutics Inc (NTLA) near the top of the Biotechnology industry according to InvestorsObserver. Intellia Therapeutics Inc's score of 79 means it scores higher than 79% of stocks in the industry. Intellia Therapeutics Inc also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Intellia Therapeutics Inc (NTLA) stock is trading at $83.77 as of 10:40 AM on Friday, Jan 8, a rise of $6.29, or 8.12% from the previous closing price of $77.48. The stock has traded between $75.64 and $86.13 so far today. Volume today is light. So far 972,367 shares have traded compared to average volume of 1,765,098 shares.

Click Here to get the full Stock Score Report on Intellia Therapeutics Inc (NTLA) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Follow this link:
Is Intellia Therapeutics Inc (NTLA) a Winner in the Biotechnology Industry? - InvestorsObserver

A rating of 82 puts Regenxbio Inc (RGNX) near the top of the Biotechnology industry according to InvestorsObserver. Regenxbio Inc's score of 82 means it scores higher than 82% of stocks in the industry. Regenxbio Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 66 would rank higher than 66 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Regenxbio Inc (RGNX) stock has fallen -2.9% while the S&P 500 has risen 0.05% as of 10:40 AM on Friday, Jan 8. RGNX has fallen -$1.44 from the previous closing price of $49.49 on volume of 833,286 shares. Over the past year the S&P 500 is higher by 16.22% while RGNX has risen 11.77%. RGNX lost -$2.48 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Regenxbio Inc (RGNX) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the rest here:
Is Regenxbio Inc (RGNX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The 37 rating InvestorsObserver gives to Stealth BioTherapeutics Corp (MITO) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 28 percent of stocks in the Biotechnology industry, MITOs 37 overall rating means the stock scores better than 37 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 37 means the stock is more attractive than 37 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Stealth BioTherapeutics Corp (MITO) stock is trading at $1.42 as of 10:38 AM on Friday, Jan 8, a rise of $0.04, or 2.9% from the previous closing price of $1.38. The stock has traded between $1.39 and $1.45 so far today. Volume today is light. So far 122,117 shares have traded compared to average volume of 815,884 shares.

Click Here to get the full Stock Score Report on Stealth BioTherapeutics Corp (MITO) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

More here:
Is Stealth BioTherapeutics Corp (MITO) a Winner in the Biotechnology Industry? - InvestorsObserver